Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Exelixis, Inc. (EXEL) -- Ignore unavailable to you. Want to Upgrade?

To: Malyshek who wrote (853)	1/23/2012 11:24:57 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 930

Would be good if someone who knows details about relative efficacy, HCC, commented. The company is for sale, and, IMO, only MTC and prostate observations are relevant to price. Any HCC trial would be large/expensive, and a snail beats NCI CRADA studies by wide margin. So.... IMO..... these results won't be viewed as important "mover" material for any potential suitor. What does Ernie at Yahoo say re. trial design and relative efficacy? Hopefully, someone who is closer to the issue will comment. Good luck!